Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.73 |
| ▸ | CACNA2D1 | P54289 | 12/20 | 0.51 |
| ▸ | CACNB1 | Q02641 | 12/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 11/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 6/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.51 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1800586 | 0.99 | SERPINE1 (0.72) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL1800427 | 0.91 | SERPINE1 (0.64) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL1798040 | 0.85 | SERPINE1 (0.75) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL1798984 | 0.85 | SERPINE1 (1.00) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL1799860 | 0.84 | SERPINE1 (0.98) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL29351719 | 0.84 | SERPINE1 (0.98) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL1798505 | 0.83 | SERPINE1 (0.71) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL539165 | 0.82 | SERPINE1 (0.70) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL418105 | 0.82 | SERPINE1 (0.69) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C | |
| Hydrochloric Acid SCHEMBL416268 | 0.81 | SERPINE1 (0.68) | SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | claimed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | claimed |
| US-10092537-B2 | Use for PAI-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2018-10-09 | — | — | US | disclosed |
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-2990057-A1 | NOVEL USE FOR PAI-1 INHIBITOR | Renascience Co., Ltd. (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885CACNA2D1 4373/4885CACNB1 4276/4885 |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885CACNA2D1 3723/4885CACNB1 3457/4885 |
| US-10092537-B2 | Use for PAI-1 inhibitor | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885CACNA2D1 4383/4885CACNB1 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.